Date: 2017-02-06
Type of information: Nomination
Compound: president
Company: Teva Pharmaceutical (Israel)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 6, 2017, Teva Pharmaceutical Industries announced that Dr. Yitzhak Peterburg , who has served as chairman of the Teva board of directors since January 2015 , has been appointed interim president and chief eExecutive officer, effective immediately. This follows the mutual agreement between the board of Teva and Erez Vigodman that Mr. Vigodman is stepping down. Mr. Vigodman's service on the Teva board of directors has also ended.
Prior to rejoining Teva's board of directors in 2012, Dr. Peterburg led the company's innovative R&D efforts as Teva's Group vice president, Global Branded Products, from October 2010 until October 2011 , after serving on Teva's board of directors from 2009 until July 2010 .
The board has elected Dr. Sol J. Barer , who has been a member of the Teva Board since January 2015 , as chairman. Dr. Barer brings deep knowledge of the global pharmaceutical industry. He was a founder of the biotechnology group at Celanese , later spun off as Celgene , where he served in top leadership roles from 1987 to 2011, including as Chairman and CEO from 2007 to 2010.
Teva's board of directors is undertaking a search to identify a permanent chief executive officer with the assistance of a search firm.
Financial terms:
Latest news:
Is general: Yes
